Condition: Ovarian Cancer Recurrent · Fallopian Tube Cancer · Primary Peritoneal Carcinoma · Sponsor: Shanghai Gynecologic Oncology Group
This is a Phase II, open-label, multicenter, randomized umbrella study to evaluate the efficacy of cytoreductive surgery and Niraparib maintenance in participants with platinum-sensitive secondary recurrent ovarian cancer. Cohort 1 will focus on participants without prior use of PARP inhibitor, and without prior secondary cytoreduction (SCR) when first recurrence. Cohort 2 will focus on participants with prior use of PARP inhibitor, but without prior SCR when first recurrence. Cohort 3 will focus on participants with SCR when first recurrence, but without prior use of PARP inhibitor.
This description comes directly from the study's public registry record.
Rong Jiang, M.D. · +862164041990 · jiang.rong@zs-hospital.sh.cn
Yuting Luan, R.N. · +862164041990 · yutingluan@163.com
Always discuss trial participation with your own doctor first.
| Fudan University Shanghai Zhongshan Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, China | Not Yet Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, China | Not Yet Recruiting |
| Fudan University | Shanghai, China | Not Yet Recruiting |
| Shanghai Jiao Tong University | Shanghai, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03983226